Ajanta Pharma, Biocon Partner to Conquer $100B Weight-Loss Drug Market

• Ajanta Pharma has partnered with Biocon to target the rapidly growing global GLP-1 weight-loss drug market, projected to reach $100 billion in five years.
• The tie-up grants Ajanta exclusive marketing rights for Semaglutide in 23 countries across Africa, West Asia, and Central Asia, leveraging its strong regional presence.
• Ajanta plans to begin filing product dossiers in Q1 FY28, expecting first approvals by the end of FY28, with meaningful revenue contributions from FY29.
• Managing Director Yogesh Agrawal emphasizes the technical and regulatory complexity limiting competition, estimating a $1 billion addressable market in their target geographies.
• Ajanta also aims to be a "first wave launcher" of Semaglutide in India post-patent expiry in March 2026 and a generic Mounjaro by 2033.

Why It Matters: Ajanta Pharma strategically enters the booming weight-loss drug market via Biocon partnership, eyeing significant global growth.